WO2002003992A3 - Use of substituted indole compounds for treating prosthesis-related bone degeneration - Google Patents
Use of substituted indole compounds for treating prosthesis-related bone degeneration Download PDFInfo
- Publication number
- WO2002003992A3 WO2002003992A3 PCT/US2001/021084 US0121084W WO0203992A3 WO 2002003992 A3 WO2002003992 A3 WO 2002003992A3 US 0121084 W US0121084 W US 0121084W WO 0203992 A3 WO0203992 A3 WO 0203992A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treating
- alkyl
- prosthesis
- formulae
- substituted indole
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 230000007850 degeneration Effects 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 150000002170 ethers Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical class 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical class *C#N 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- SMYMDRJWEFCCCI-UHFFFAOYSA-N trichloro(trichloromethoxy)methane Chemical compound ClC(Cl)(Cl)OC(Cl)(Cl)Cl SMYMDRJWEFCCCI-UHFFFAOYSA-N 0.000 abstract 1
- WZEOZJQLTRFNCU-UHFFFAOYSA-N trifluoro(trifluoromethoxy)methane Chemical compound FC(F)(F)OC(F)(F)F WZEOZJQLTRFNCU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical class FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention comprises methods of treating bone prosthesis degeneration comprising administration of a compound of formulae (I) or (II), wherein Z is a moiety selected from the group of formulae (a, b or c), wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH; Y is the moiety of formulae (d), R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof, and optionally an estrogen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2001271784A AU2001271784A1 (en) | 2000-07-06 | 2001-06-29 | Therapy for prosthesis-related bone degeneration |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21640700P | 2000-07-06 | 2000-07-06 | |
| US21640600P | 2000-07-06 | 2000-07-06 | |
| US60/216,407 | 2000-07-06 | ||
| US60/216,406 | 2000-07-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002003992A2 WO2002003992A2 (en) | 2002-01-17 |
| WO2002003992A3 true WO2002003992A3 (en) | 2002-06-27 |
Family
ID=26910981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/021084 WO2002003992A2 (en) | 2000-07-06 | 2001-06-29 | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001271784A1 (en) |
| WO (1) | WO2002003992A2 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003248707A1 (en) * | 2002-06-13 | 2003-12-31 | Wyeth | Bazedoxifene treatment regimens |
| EP1545206B1 (en) | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| JP4889944B2 (en) | 2002-10-29 | 2012-03-07 | コロラド ステート ユニバーシティー リサーチ ファウンデーション | Use of equol to treat androgen-mediated diseases |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| JO3112B1 (en) | 2010-03-29 | 2017-09-20 | Ferring Bv | A fast dissolving pharmaceutical composition |
| PL2552418T3 (en) | 2010-03-29 | 2017-12-29 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| NZ779654A (en) | 2015-10-01 | 2024-12-20 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
| HRP20221462T1 (en) | 2015-12-09 | 2023-01-20 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| ES2989988T3 (en) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Heterocyclic degronimers for the degradation of target proteins |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
| ES2990061T3 (en) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Spirocyclic degronimers for the degradation of target proteins |
| CN109789143A (en) | 2016-07-01 | 2019-05-21 | G1治疗公司 | Antiproliferative based on pyrimidine |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| CN110177554B (en) | 2017-01-06 | 2023-06-02 | G1治疗公司 | Combination Therapies Used to Treat Cancer |
| CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| BR112019027967A2 (en) | 2017-06-29 | 2020-07-14 | G1 Therapeutics, Inc. | isolated crystalline form b, pharmaceutical composition, method for treating a disorder, method of a compound or composition, and, process for producing crystalline form b. |
| CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
| CN118344370A (en) | 2019-12-20 | 2024-07-16 | C4医药公司 | Isoindolinone and indazole compounds for EGFR degradation |
| CN115279370B (en) | 2020-03-05 | 2025-01-10 | C4医药公司 | Compounds for targeted degradation of BRD9 |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED RET DEGRADATION |
| CN119998285A (en) | 2022-08-03 | 2025-05-13 | 百时美施贵宝公司 | Compounds for modulating RET proteins |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005824A1 (en) * | 1994-08-22 | 1996-02-29 | Eli Lilly And Company | Methods for inhibiting bone prosthesis degeneration |
| EP0802184A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | N-Benzyl-2-phenylindoles as estrogenic agents |
| EP0802183A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | Estrogenic agents |
| US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| WO1999059581A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
| WO1999059969A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
| EP1123717A2 (en) * | 2000-01-26 | 2001-08-16 | Pfizer Products Inc. | Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
-
2001
- 2001-06-29 WO PCT/US2001/021084 patent/WO2002003992A2/en active Application Filing
- 2001-06-29 AU AU2001271784A patent/AU2001271784A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005824A1 (en) * | 1994-08-22 | 1996-02-29 | Eli Lilly And Company | Methods for inhibiting bone prosthesis degeneration |
| EP0802184A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | N-Benzyl-2-phenylindoles as estrogenic agents |
| EP0802183A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | Estrogenic agents |
| US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| WO1999059581A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
| WO1999059969A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
| EP1123717A2 (en) * | 2000-01-26 | 2001-08-16 | Pfizer Products Inc. | Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE DRUGNL [online] "TSE 424", XP002195073, retrieved from STN Database accession no. 2000:1286 * |
| R&D FOCUS DRUG NEWS, 17 April 2000 (2000-04-17) * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002003992A2 (en) | 2002-01-17 |
| AU2001271784A1 (en) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002003992A3 (en) | Use of substituted indole compounds for treating prosthesis-related bone degeneration | |
| WO2002003986A3 (en) | Use of substituted indole compounds for treating breast disorders | |
| WO2002003976A3 (en) | Combinations of bisphosphonates, estrogenic agents and optionally estrogens | |
| WO2002003991A3 (en) | Use of substituted indole compounds for increasing nitric oxide synthase activity | |
| WO2002003988A3 (en) | Use of substituted indole compounds for treating neuropeptide y-related conditions | |
| WO2002003977A3 (en) | Combinations of statins, estrogenic agents and optionally estrogens | |
| WO2002003990A3 (en) | Use of substituted insole compounds for treating excessive intraocular pressure | |
| WO2002003989A3 (en) | Use of substituted indole compounds for treating sphincter incontinence | |
| WO2002003987A3 (en) | Pharmaceutical compositions of estrogenic agents | |
| WO2002004418A3 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
| DK1299348T3 (en) | Compounds and compositions for delivery of active agents | |
| NO20024891L (en) | Pharmaceutical compositions | |
| CA2288910A1 (en) | Pyrazolopyrimidinones for sexual dysfunction | |
| CA2372560A1 (en) | Cyanopyrroles for binding the progesterone receptor | |
| MXPA05008364A (en) | Pyrimidine derivatives for the prevention of hiv infection. | |
| EP1040823A3 (en) | Stable foam compositions | |
| PE20080689A1 (en) | KINASE INHIBITORS AMINE DERIVATIVES | |
| HUP0402336A2 (en) | Thieno[2,3-d]pyrimidine-2,4-dione derivatives, process for their preparation, their use in the modulation of autoimmune disease and pharmaceutical compositions containing them | |
| NZ518542A (en) | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | |
| HUP0002461A2 (en) | Tricyclic benzothiepin a benzoxepin derivatives and pharmaceutical compositions thereof | |
| AP2001002302A0 (en) | 13-Methyl erythromycin derivatives. | |
| MY136824A (en) | Substituted benzoxazinones and uses thereof | |
| EP1277744A4 (en) | Oxadiazole derivatives having anticancer effects | |
| MY138826A (en) | 2,7-substituted indoles | |
| EP1057819A4 (en) | Phthalazine derivatives and remedies for erectile dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |